Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompoSIT-I: Sitagliptin Continuation vs Withdrawal with Insulin Glargine Initiation
NCT02738879Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started May 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02738879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738879.